solifenacin (Vesicare)

From Aaushi
Jump to navigation Jump to search

Introduction

Tradenames: Vesicare (scheduled for release late 2004)

Indications

Contraindications

pregnancy category = c

Dosage

5-10 mg PO QD (no dose adjustment in the elderly)[4]

Dosage adjustment in renal failure

Pharmacokinetics

protein binding = 98 %

1/2life = 45-68 hours

Adverse effects

(% for 10 mg QD)

Drug interactions

Mechanism of action

More general terms

Component of

References

  1. Prescriber's Letter 11(9): 2004 Detail-Document#: http://prescribersletter.com/(5bhgn1a4ni4cyp2tvybwfh55)/pl/ArticleDD.aspx?li=1&st=1&cs=&s=PRL&pt=3&fpt=25&dd=200910&pb=PRL (subscription needed) http://www.prescribersletter.com
  2. Prescriber's Letter 12(2): 2005 Antimuscarinic Medications for Overactive Bladder Detail-Document#: http://prescribersletter.com/(5bhgn1a4ni4cyp2tvybwfh55)/pl/ArticleDD.aspx?li=1&st=1&cs=&s=PRL&pt=3&fpt=25&dd=210209&pb=PRL (subscription needed) http://www.prescribersletter.com
  3. 3.0 3.1 http://www.vesicare.com
  4. 4.0 4.1 Erdem M & Chu FM Management of overactive bladder and urge urinary incontinence in the elderly patient. Am J Med 2006;119(3A):295
  5. Deprecated Reference

Database